REGN

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

Is AbbVie a Buy After Its Purchase of Apogee?